Dostarlimab Plus Chemo Expands Frontline Options in Advanced/Recurrent Endometrial Cancer

Following the August 2024 decision by the FDA to expand the approval of dostarlimab-gxly (Jemperli) plus chemotherapy to include the frontline treatment of patients with primary advanced or recurrent endometrial cancer, patients now have greater…